Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2102 in HER2-positive Advanced Biliary Tract Cancer
NCT06431490Phase 2Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jul 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2102 in biliary tract cancer (BTC), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Jul 2024; status: recruiting.
02
Drugs
TQB2102
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06431490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06431490.